Alf Gunnar Martin Nicklasson is a Swedish businessperson who has been at the head of 14 different companies. Currently, he occupies the position of Chairman at Zealand Pharma A, Chairman at Nykode Therapeutics ASA, Chairman for Sanivo Pharma AS and Non-Executive Chairman for Kymab Ltd.
He is also on the board of Basilea Pharmaceutica AG (former Chairman), BioCrine AB, Stockholm Chamber of Commerce and Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt and Associate Professor at the University of Uppsala, Member of Royal Swedish Academy of Engineering Sciences, Member of The Royal Bachelors' Club, Member of Swedish Academy For Pharmaceutical Sciences and Senior Partner at Nicklasson Life Science AB.
He previously was Chairman for Orexo AB, Chairman for Orexo AB, Chairman at Farma Investment AS, Chief Executive Officer at Astra Hässle AB, President & Chief Executive Officer of Swedish Orphan Biovitrum AB President & Chief Executive Officer at Biovitrum AB and Chief Executive Officer at Swedish Orphan International Holding AB (both are subsidiaries of Swedish Orphan Biovitrum AB), Chief Executive Officer for Astra Pain Control AB and EVP-Product Strategy & Business Development at AstraZeneca PLC and Chief Executive Officer for AstraZeneca AB (a subsidiary of AstraZeneca PLC).
Alf Gunnar Martin Nicklasson received a graduate degree and a doctorate from the University of Uppsala.